The DOT testing at HHS-certified laboratories is a 5-panel drug test regimen. As of January 1, 2018, the ‘Opiates’ category was renamed ‘Opioids’:
Under ‘Opioids’, previously ‘Opiates’, DOT testing will continue to include confirmatory testing, when appropriate, for Codeine, Morphine, and 6-AM (heroin). We added initial and confirmatory testing for the semi-synthetic opioids Hydrocodone, Hydromorphone, Oxycodone, and Oxymorphone to this Opioids group. Some brand names for the semi-synthetic opioids include OxyContin®, Percodan®, Percocet®, Vicodin®, Lortab®, Norco®, Dilaudid®, Exalgo®.
Under Amphetamines, DOT testing includes confirmatory testing, when appropriate, for Amphetamine, Methamphetamine, MDMA, and MDA. To this Amphetamines group, we added initial testing for MDA and removed testing for MDEA.
Since January 1st, we have required confirmation testing for 14 drugs under a 5‑panel test. Broken out, here is what DOT drug testing looks like:
For DOT testing, what does this mean for collectors, laboratories, MROs, and employers after January 1st 2018
WeAssure Biometrics and Screening Services
Kansas City, Missouri
Copyright © 2025 WeAssure Biometrics and Screening Services - All Rights Reserved.